Gao Changshou

Responsible for the related work of the National Institute of Qing Dynasty and the International R&D Center. Dr. Gao received his master's degree from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and his Ph.D. from the Department of Chemistry and Molecular Biology, Scripps Research Institute (La Jolla), USA.

Dr. Gao has more than 30 years of academic research achievements and nearly 20 years of experience in biopharmaceutical development and team management in international pharmaceutical companies, with excellent scientific research and innovation capabilities. Before joining Innovent, Dr. Gao worked as a senior director at MedImmune, a global biopharmaceutical R&D platform under AstraZeneca, and has been focusing on antibody discovery & protein engineering research for 18 years. Dr. Gao has expertise in antibody discovery/engineering, protein engineering, bispecific antibodies, antibody drug conjugates (ADCs), large-scale antibody transient expression, targeted nanoparticles, PROTACs, adeno-associated virus (AAV)-mediated gene therapy, As well as extensive experience in the development of new technologies for next-generation biologics. He has successfully led the advancement of more than 20 new drugs, including ADCs and bispecific antibody drugs, into the clinical research stage, covering multiple disease fields such as tumors, immunity, infectious diseases, cardiovascular, and metabolism.

Dr. Gao has published more than 70 articles in major academic journals (h index = 32, more than 3300 citations), and has been authorized or applied for 38 patents.